查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1969270

運動障礙市場：依運動障礙類型、治療方法、給藥途徑、患者照護環境和最終使用者分類－2026-2032年全球預測

Dyskinesia Market by Dyskinesia Type, Treatment Type, Route of Administration, Patient Care Settings, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，運動障礙市場價值將達到 36.6 億美元，到 2026 年將成長至 39.3 億美元，到 2032 年將達到 61 億美元，複合年成長率為 7.55%。

主要市場統計數據
基準年 2025 36.6億美元
預計年份：2026年 39.3億美元
預測年份 2032 61億美元
複合年成長率 (%) 7.55%

對運動障礙的引人入勝的介紹：整合了臨床定義、患者和看護者的負擔、診斷的複雜性、未滿足的需求以及研究的必要性。

運動障礙是一組複雜的運動過度症，病因多樣，為患者及其看護者帶來顯著的臨床挑戰和生活品質（QOL）問題。不同專科對運動障礙的定義與分類各不相同，導致診斷複雜，治療方案也多元。因此，臨床醫生必須結合細緻的表現型分析和縱向評估，以區分波動性舞蹈症、持續性肌張力不全症姿勢和局部肌陣攣等症狀。這種多樣性要求制定個人化的治療方案，以平衡症狀控制和功能維持。

本文概述了透過治療創新、數位健康整合、不斷發展的支付方框架和監管改革，運動障礙領域正在發生的變革性轉變。

近年來，臨床實踐、治療研發和醫療技術的變革性變化正在改變我們對運動障礙的理解和治療方式。神經生理監測和數位表現型分析的進步使得運動模式的表徵更加精細，從而支持標靶治療策略和客觀療效評估。同時，新型藥理機制和神經調控技術的不斷完善，拓展了臨床醫師可用的治療手段，使其能夠更精準地調控異常運動迴路。

對計劃於 2025 年實施的美國關稅調整將如何影響醫療設備和藥品的供應鏈、治療取得以及跨境合作進行嚴格評估。

影響跨境貿易的政策變化，包括美國將於2025年實施的關稅調整，將對整個運動障礙治療生態系統產生連鎖反應，影響醫療設備、專用診斷設備和藥品原料的流通。供應鏈相關人員正在重新審視籌資策略、庫存管理政策和供應商關係，以減輕潛在的供應中斷。特別是神經調控硬體和輸注系統的製造商和經銷商，可能需要調整其物流和零件採購策略，以確保向治療中心和專科診所的供應持續性。

基於細分的深入分析揭示了每種非自主運動亞型、治療方法、給藥途徑和醫療保健環境的不同臨床需求和商業策略。

針對特定細分市場的趨勢揭示了臨床需求和服務設計中的細微模式，這些模式應指南產品開發和護理策略。在按類型細分運動障礙時，手足徐動症、舞蹈症、肌張力不全症相關性運動障礙、肌陣攣性運動障礙、帕金森氏症運動障礙、痙攣性斜頸和遲發性運動障礙各自具有不同的病理學和症狀特徵，因此需要針對每種類型製定相應的診斷演算法和治療方法。例如，一種對持續性肌張力不全症姿勢有效的治療方法可能不適用於陣發性舞蹈樣運動，臨床試驗必須在終點和表現型選擇上考慮這些差異。

一項策略性區域分析，重點分析了美洲、歐洲、中東和非洲以及亞太地區在臨床實踐、監管管道、報銷趨勢和服務提供模式方面的差異。

區域特徵顯著影響臨床路徑、監管預期和醫療體系的接受度，導致創新採納環境的差異。儘管美洲的臨床實踐中以整合的神經病學網路和成熟的醫療設備採納環境為主導，但不同支付方的報銷方案各異，因此需要製定適應性強的商業策略，以在不同的支付方環境下展現價值。區域內的跨境合作有助於臨床研究和實踐創新成果的快速傳播，但相關人員要求持續調整結果指標。

對致力於運動障礙治療的公司進行業務策略、投資組合優先排序、臨床研發管線活動、夥伴關係模式和商業化策略的全面管理分析。

在運動障礙領域，企業行為和動態受投資組合選擇、研究優先順序以及對跨學科合作的投資意願的影響。領先機構通常奉行平衡策略，將現有療法的短期最佳化與對新型作用機制和神經調控技術的長期投資相結合。醫療設備製造商、生物製藥開發公司和學術機構之間的策略聯盟能夠加速轉化研究，並使各方共享臨床網路資源，從而進行臨床試驗和上市後監測。

一項切實可行的行動計劃，為行業領導者提供優先建議，以加強研發重點、降低供應鏈風險、改善患者就醫途徑並協調相關人員的獎勵。

產業領導者應優先考慮能夠兼顧臨床價值、營運韌性和相關人員參與的切實可行的措施。首先，投資於後期臨床項目和觀察性研究，利用客觀的數位生物標記和患者報告結局來證明其在多種運動障礙症狀方面具有顯著療效。這將使申辦方能夠支持醫保報銷談判，並建立強力的證據包，從而促進指南的製定。其次，透過加強供應鏈策略，實現零件來源多元化和區域製造地擴張，從而確保關鍵醫療設備和治療藥物的可及性，並降低關稅和物流風險。

對調查方法進行透明的解釋，包括分析中使用的來源選擇、定性和定量整合方法、專家諮詢過程和檢驗通訊協定。

本分析整合了同行評審文獻、臨床指南、監管指導文件、專家訪談以及匯總的臨床項目資訊披露資訊，以確保結論具有平衡性和檢驗。數據選擇優先考慮專業學會的最新主要調查和共識聲明，並輔以來自神經科、康復專家、醫療設備工程師和支付方顧問的定性資訊，以反映實際操作情況和決策標準。此外，還使用了已發表的病例係列和註冊數據，以闡明臨床異質性和真實世界的治療模式。

本報告提供了簡潔的結論，總結了對臨床醫生、製造商、支付方、監管機構和患者權益倡導者的戰略意義，以及改善運動障礙治療效果的切實可行的後續步驟。

臨床複雜性、不斷發展的技術以及不斷變化的政策環境揭示了運動障礙的動態發展狀態，這既需要有針對性的創新，也需要系統性的調整。臨床醫生必須利用數位化測量和多學科協作，不斷改進基於表現型的治療，並最佳化治療效果。同時，研發人員和製造商應使其研發策略與實際的交付限制相符，並投資於能夠與現有治療路徑和報銷機制相整合的治療方法和服務模式。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 運動障礙市場：非自主運動的類型

  • 手足徐動症
  • 舞蹈症
  • 肌張力不全症相關運動障礙
  • 肌陣攣性運動障礙
  • 帕金森氏症運動障礙
  • 痙攣性斜頸
  • 遲發性運動障礙

第9章：依治療方法分類的運動障礙市場

  • 非藥物療法
    • 行為療法
    • 物理治療與復健
  • 藥物治療
    • 抗膽鹼能藥物
    • 多巴胺調節劑
    • GABA能促效劑
    • NMDA受體拮抗劑
    • VMAT2抑制劑
  • 手術治療方法
    • 切除手術
    • 深部腦部刺激（DBS）

第10章：運動障礙藥物市場：依給藥途徑分類

  • 靜脈注射（IV）和輸液
  • 口服
  • 皮下注射
  • 經皮

第11章患者照護環境分類的運動障礙市場

  • 居家照護
  • 醫院
  • 研究機構
  • 專科診所及復健中心

第12章 運動障礙市場：依最終使用者分類

  • 居家醫療環境
  • 醫院和診所
    • 住院服務
    • 門診醫療服務
  • 長期照護機構
  • 運動障礙專科中心

第13章 運動障礙市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：運動障礙市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 運動障礙市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國運動障礙市場

第17章：中國運動障礙市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Addex Therapeutics Ltd.
  • Bukwang Pharmaceutical Co., Ltd
  • Clearmind Medicine Inc.
  • Ipsen Pharma SAS
  • IRLAB Therapeutics AB
  • Luye Pharma Group Ltd.
  • Medtronic PLC
  • Melior Pharmaceuticals
  • Mitsubishi Tanabe Pharma Corporation
  • Motac France Sarl
  • Neurocrine Biosciences, Inc.
  • Neurolixis Inc.
  • PharmaTher Holdings Ltd.
  • Prilenia Therapeutics BV
  • ReCode Therapeutics, Inc.
  • Serina Therapeutics, Inc.
  • SOM INNOVATION BIOTECH, SA
  • Supernus Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Toray Industries, Inc.
  • Vistagen Therapeutics, Inc.
  • Voyager Therapeutics, Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-535C6291879B

The Dyskinesia Market was valued at USD 3.66 billion in 2025 and is projected to grow to USD 3.93 billion in 2026, with a CAGR of 7.55%, reaching USD 6.10 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.66 billion
Estimated Year [2026] USD 3.93 billion
Forecast Year [2032] USD 6.10 billion
CAGR (%) 7.55%

A compelling introduction to dyskinesia that synthesizes clinical definitions, patient and caregiver burden, diagnostic complexity, unmet needs, and research imperatives

Dyskinesia encompasses a complex set of hyperkinetic movement disorders that arise from diverse etiologies and present significant clinical and quality-of-life challenges for patients and caregivers. Definitions and classifications vary across specialties, which contributes to diagnostic complexity and heterogeneous treatment pathways. Consequently, clinicians must combine careful phenotyping with longitudinal assessment to distinguish among presentations such as fluctuating chorea, sustained dystonic postures, or focal myoclonic jerks. This heterogeneity drives the need for individualized care plans that balance symptomatic control with preservation of function.

Beyond clinical heterogeneity, dyskinesia imposes substantial psychosocial and functional burdens that ripple across families and health systems. Patients frequently face impaired mobility, communication difficulties, social isolation, and reduced employment opportunities, while caregivers manage escalating demands for supervision and rehabilitation. These realities underline the necessity for integrated care models that coordinate neurology, rehabilitation, and mental health services. Moving forward, stakeholders increasingly prioritize interventions that address both motor symptoms and associated nonmotor sequelae, and they emphasize patient-centered outcome measures to capture meaningful change across the disease trajectory.

An outline of transformative shifts reshaping the dyskinesia landscape through therapeutic innovation, digital health integration, evolving payer frameworks, and regulatory reform

Recent years have seen transformative shifts across clinical practice, therapeutic development, and health technology that are reshaping how dyskinesia is understood and managed. Advances in neurophysiological monitoring and digital phenotyping enable more granular characterization of movement patterns, which in turn supports targeted therapeutic strategies and objective outcome measurement. In parallel, novel pharmacological mechanisms and refinements in neuromodulation expand the therapeutic toolkit available to clinicians, allowing more precise modulation of aberrant motor circuits.

At the same time, digital health integration and remote-monitoring platforms are changing care delivery by facilitating continuous symptom tracking, medication adherence support, and virtual rehabilitation. These technologies accelerate iterative learning in clinical programs and open new pathways for decentralized trials. Regulatory landscapes and payer expectations are also evolving; stakeholders increasingly demand real-world evidence and patient-reported outcomes to validate clinical benefit. Consequently, collaborations across industry, academia, and clinical networks are becoming central to advancing translational research and aligning product development with practical implementation needs.

A rigorous assessment of how United States tariff changes slated for 2025 could alter medical device and pharmaceutical supply chains, access to therapies, and cross-border collaborations

Policy changes that affect cross-border trade, including tariff adjustments implemented by the United States in 2025, have implications across the dyskinesia ecosystem by influencing the flow of medical devices, specialized diagnostic equipment, and pharmaceutical inputs. Supply chain stakeholders are reassessing sourcing strategies, inventory policies, and vendor relationships to mitigate potential disruptions. In particular, manufacturers and distributors of neuromodulation hardware and infusion systems may need to re-examine logistics and component sourcing to preserve continuity of supply to treatment centers and specialty clinics.

In addition, clinical research programs that rely on global collaboration and device transfer face more complex operational requirements when tariffs alter the economics of shipping and local manufacturing. Procurement teams within hospitals, specialty centers, and long-term care facilities must adapt contracting and purchasing cycles to maintain access to essential therapies. In response, many organizations are intensifying supplier diversification, increasing regional manufacturing partnerships, and exploring alternative distribution models to retain resilience. These near-term adjustments are likely to influence longer-term commercial planning and partnership structures across the therapeutic landscape.

A focused analysis of segmentation-driven insights that illuminate differential clinical needs and commercial strategies across dyskinesia subtypes, treatment types, administration routes, and care settings

Segment-specific dynamics reveal nuanced patterns of clinical need and service design that should inform product development and care strategies. When considering dyskinesia type segmentation, distinct pathophysiologies and symptom profiles characterize Athetosis, Chorea, Dystonia-Related Dyskinesia, Myoclonic Dyskinesia, Parkinson's Dyskinesia, Spasmodic Torticollis, and Tardive Dyskinesia, each demanding tailored diagnostic algorithms and therapeutic approaches. For example, treatments that effectively address sustained dystonic postures may not translate to paroxysmal choreiform movements, and clinical trials must account for these differences in endpoint selection and phenotypic enrichment.

Looking across treatment type segmentation, non-pharmacological approaches such as behavioral therapy and physical therapy & rehabilitation play foundational roles in functional restoration, while pharmacological treatments deliver symptomatic modulation through anticholinergics, dopamine modulators, GABA agonists, NMDA receptor antagonists, and VMAT2 inhibitors. Surgical options remain critical for refractory cases, and ablative surgery and deep brain stimulation (DBS) offer distinct risk-benefit profiles that clinicians weigh against symptom severity and patient goals. Route of administration segmentation underscores how intravenous and infusion-based therapies, oral agents, subcutaneous formulations, and transdermal systems create different adherence, monitoring, and delivery considerations, particularly for patients in homecare settings.

Patient care settings and end-user segmentation further shape commercialization and service models. Home care, hospitals, research institutes, and specialty clinics & rehabilitation centers each require unique training, monitoring, and equipment. End users such as homecare settings, hospitals & clinics with both inpatient and outpatient services, long-term care facilities, and specialty movement disorder centers show variable capacity for advanced therapies and multidisciplinary management. Integrating these segmentation insights enables more targeted clinical development, reimbursement strategies, and implementation roadmaps that reflect real-world constraints and opportunities.

A strategic regional analysis that highlights clinical practice variation, regulatory pathways, reimbursement dynamics, and service delivery models across the Americas, Europe, Middle East & Africa, and Asia-Pacific landscapes

Regional characteristics exert meaningful influence on clinical pathways, regulatory expectations, and health system capacity, creating differentiated environments for innovation adoption. In the Americas, clinical practice patterns emphasize integrated neurology networks and a mature device adoption landscape, yet reimbursement heterogeneity across payers requires adaptive commercial strategies that can demonstrate value in diverse payer contexts. Cross-border collaboration within the region supports clinical research and rapid dissemination of practice innovations, but stakeholders must continuously align on standards for outcome measurement.

Across Europe, the Middle East & Africa, regulatory frameworks and reimbursement models vary widely, with some countries demonstrating strong centralized HTA processes and others relying on local hospital-level decision-making. These differences affect timing of access and the types of evidence that are persuasive to payers and providers. Meanwhile, Asia-Pacific features a mix of rapidly advancing clinical infrastructure and high-capacity centers alongside regions where access to specialized therapies remains constrained. As a result, regional partnerships, local manufacturing options, and culturally adapted care models play a key role in expanding access to advanced treatments. Taken together, geographic nuances underscore the importance of regionally tailored clinical development plans, regulatory strategies, and stakeholder engagement frameworks to ensure sustainable implementation of dyskinesia innovations.

An executive synthesis of corporate strategies, portfolio prioritization, clinical pipeline activity, partnership models, and commercialization tactics among firms shaping dyskinesia care

Corporate behavior and competitive dynamics in dyskinesia are shaped by portfolio choices, research prioritization, and the willingness to invest in multidisciplinary collaborations. Leading organizations often pursue balanced strategies that combine near-term optimization of existing therapies with longer-term investments in novel mechanisms and neuromodulation technologies. Strategic partnerships between device manufacturers, biopharmaceutical developers, and academic centers accelerate translational work and enable shared access to clinical networks for trials and post-market studies.

Commercial differentiation increasingly hinges on integrated service offerings that pair therapeutic modalities with digital monitoring, patient support programs, and data-driven outcomes measurement. Companies that develop robust real-world evidence programs and cultivate strong relations with specialty movement disorder centers and payer stakeholders are better positioned to articulate value propositions and streamline adoption. Additionally, supply chain resilience and regulatory expertise remain important competitive levers; organizations investing in diversified sourcing, local manufacturing partnerships, and proactive regulatory engagement can reduce operational risk while improving time-to-care for patients in fragmented health system environments.

A pragmatic action plan offering prioritized recommendations for industry leaders to strengthen R&D focus, de-risk supply networks, improve patient pathways, and align stakeholder incentives

Industry leaders should prioritize a set of actionable initiatives that align clinical value with operational resilience and stakeholder engagement. First, invest in late-stage clinical programs and observational studies that employ objective digital biomarkers and patient-reported outcomes to demonstrate meaningful benefit across heterogeneous dyskinesia presentations. By doing so, sponsors can build persuasive evidence packages that support reimbursement discussions and inform guideline development. Second, strengthen supply chain strategies by diversifying component sourcing and expanding regional manufacturing options to mitigate tariff-related and logistical risks, thereby preserving access to critical devices and therapeutics.

Third, embed care delivery innovations by partnering with specialty centers, homecare providers, and rehabilitation networks to create integrated pathways that combine pharmacology, surgical options, and rehabilitative support. Such partnerships should include training initiatives to ensure consistent quality of care and proper utilization of advanced therapies. Fourth, accelerate commercial readiness by designing flexible pricing and contracting models that reflect heterogeneity across payers and providers, coupled with real-world evidence commitments to demonstrate sustained value. Finally, foster collaborative research ecosystems by aligning with academic consortia and patient advocacy organizations to co-develop outcome measures, improve trial recruitment, and ensure that product development remains responsive to lived experience and clinical priorities.

A transparent research methodology description covering source selection, qualitative and quantitative synthesis methods, expert consultation processes, and validation protocols used in the analysis

This analysis synthesizes evidence from peer-reviewed literature, clinical guidelines, regulatory guidance documents, expert interviews, and aggregated clinical program disclosures to ensure a balanced and verifiable foundation for conclusions. Data selection prioritized recent primary research and consensus statements from specialty societies, complemented by qualitative inputs from neurologists, rehabilitation specialists, device engineers, and payer advisors to capture operational realities and decision-making criteria. In addition, published case series and registry data were used to contextualize clinical heterogeneity and real-world treatment patterns.

The review applied structured evidence synthesis techniques, combining thematic qualitative analysis with cross-validation from subject-matter experts to identify convergent insights and areas of uncertainty. Validation protocols included triangulating clinical assertions against guideline recommendations and soliciting feedback from external clinicians who manage complex dyskinesia cases. Throughout the process, transparency and reproducibility were emphasized by documenting source provenance and methodological choices, while acknowledging limitations where evidence gaps remain. This approach supports credible interpretation of the landscape and informs practical recommendations for stakeholders.

A concise conclusion that distills strategic implications for clinicians, manufacturers, payers, regulators, and patient advocates and outlines pragmatic next steps to improve dyskinesia outcomes

Synthesizing clinical complexity, evolving technologies, and shifting policy contexts reveals a dynamic dyskinesia landscape in which targeted innovation and system-level adaptation are both required. Clinicians must continue to refine phenotype-driven care, leveraging digital measurement and multidisciplinary collaboration to optimize outcomes. At the same time, developers and manufacturers should align development strategies with practical delivery constraints, investing in therapies and service models that integrate with existing care pathways and reimbursement realities.

Policymakers and purchasers can accelerate meaningful access by recognizing the heterogeneity of dyskinesia presentations and by supporting flexible evidence paradigms that reward functional improvements and patient-centered outcomes. Finally, cross-sector collaboration-linking academic research, clinical centers, industry, and patient advocacy-remains essential to close evidence gaps and scale high-impact interventions. Taken together, these strategic implications point to a coordinated agenda that balances innovation with implementability to improve care for individuals affected by dyskinesia.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dyskinesia Market, by Dyskinesia Type

  • 8.1. Athetosis
  • 8.2. Chorea
  • 8.3. Dystonia-Related Dyskinesia
  • 8.4. Myoclonic Dyskinesia
  • 8.5. Parkinson's Dyskinesia
  • 8.6. Spasmodic Torticollis
  • 8.7. Tardive Dyskinesia

9. Dyskinesia Market, by Treatment Type

  • 9.1. Non-Pharmacological Approaches
    • 9.1.1. Behavioral Therapy
    • 9.1.2. Physical Therapy & Rehabilitation
  • 9.2. Pharmacological Treatments
    • 9.2.1. Anticholinergics
    • 9.2.2. Dopamine Modulators
    • 9.2.3. GABA Agonists
    • 9.2.4. NMDA Receptor Antagonists
    • 9.2.5. VMAT2 Inhibitors
  • 9.3. Surgical Treatments
    • 9.3.1. Ablative Surgery
    • 9.3.2. Deep Brain Stimulation (DBS)

10. Dyskinesia Market, by Route of Administration

  • 10.1. Intravenous (IV) & Infusion-Based
  • 10.2. Oral
  • 10.3. Subcutaneous
  • 10.4. Transdermal

11. Dyskinesia Market, by Patient Care Settings

  • 11.1. Home Care
  • 11.2. Hospitals
  • 11.3. Research Institutes
  • 11.4. Specialty Clinics & Rehabilitation Centers

12. Dyskinesia Market, by End User

  • 12.1. Homecare Settings
  • 12.2. Hospitals & Clinics
    • 12.2.1. Inpatient Services
    • 12.2.2. Outpatient Services
  • 12.3. Long-Term Care Facilities
  • 12.4. Specialty Movement Disorder Centers

13. Dyskinesia Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Dyskinesia Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Dyskinesia Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Dyskinesia Market

17. China Dyskinesia Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AbbVie Inc.
  • 18.7. Addex Therapeutics Ltd.
  • 18.8. Bukwang Pharmaceutical Co., Ltd
  • 18.9. Clearmind Medicine Inc.
  • 18.10. Ipsen Pharma SAS
  • 18.11. IRLAB Therapeutics AB
  • 18.12. Luye Pharma Group Ltd.
  • 18.13. Medtronic PLC
  • 18.14. Melior Pharmaceuticals
  • 18.15. Mitsubishi Tanabe Pharma Corporation
  • 18.16. Motac France Sarl
  • 18.17. Neurocrine Biosciences, Inc.
  • 18.18. Neurolixis Inc.
  • 18.19. PharmaTher Holdings Ltd.
  • 18.20. Prilenia Therapeutics B.V.
  • 18.21. ReCode Therapeutics, Inc.
  • 18.22. Serina Therapeutics, Inc.
  • 18.23. SOM INNOVATION BIOTECH, SA
  • 18.24. Supernus Pharmaceuticals, Inc.
  • 18.25. Teva Pharmaceutical Industries Ltd.
  • 18.26. Toray Industries, Inc.
  • 18.27. Vistagen Therapeutics, Inc.
  • 18.28. Voyager Therapeutics, Inc.
  • 18.29. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL DYSKINESIA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DYSKINESIA MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DYSKINESIA MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DYSKINESIA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DYSKINESIA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DYSKINESIA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DYSKINESIA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DYSKINESIA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DYSKINESIA MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DYSKINESIA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DYSKINESIA MARKET SIZE, BY ATHETOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DYSKINESIA MARKET SIZE, BY ATHETOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DYSKINESIA MARKET SIZE, BY ATHETOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DYSKINESIA MARKET SIZE, BY CHOREA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DYSKINESIA MARKET SIZE, BY CHOREA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DYSKINESIA MARKET SIZE, BY CHOREA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DYSKINESIA MARKET SIZE, BY DYSTONIA-RELATED DYSKINESIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DYSKINESIA MARKET SIZE, BY DYSTONIA-RELATED DYSKINESIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DYSKINESIA MARKET SIZE, BY DYSTONIA-RELATED DYSKINESIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DYSKINESIA MARKET SIZE, BY MYOCLONIC DYSKINESIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DYSKINESIA MARKET SIZE, BY MYOCLONIC DYSKINESIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DYSKINESIA MARKET SIZE, BY MYOCLONIC DYSKINESIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DYSKINESIA MARKET SIZE, BY PARKINSON'S DYSKINESIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DYSKINESIA MARKET SIZE, BY PARKINSON'S DYSKINESIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DYSKINESIA MARKET SIZE, BY PARKINSON'S DYSKINESIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DYSKINESIA MARKET SIZE, BY SPASMODIC TORTICOLLIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DYSKINESIA MARKET SIZE, BY SPASMODIC TORTICOLLIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DYSKINESIA MARKET SIZE, BY SPASMODIC TORTICOLLIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DYSKINESIA MARKET SIZE, BY TARDIVE DYSKINESIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DYSKINESIA MARKET SIZE, BY TARDIVE DYSKINESIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DYSKINESIA MARKET SIZE, BY TARDIVE DYSKINESIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DYSKINESIA MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DYSKINESIA MARKET SIZE, BY BEHAVIORAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DYSKINESIA MARKET SIZE, BY BEHAVIORAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DYSKINESIA MARKET SIZE, BY PHYSICAL THERAPY & REHABILITATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DYSKINESIA MARKET SIZE, BY PHYSICAL THERAPY & REHABILITATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DYSKINESIA MARKET SIZE, BY PHYSICAL THERAPY & REHABILITATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DYSKINESIA MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DYSKINESIA MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DYSKINESIA MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DYSKINESIA MARKET SIZE, BY DOPAMINE MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DYSKINESIA MARKET SIZE, BY DOPAMINE MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DYSKINESIA MARKET SIZE, BY DOPAMINE MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DYSKINESIA MARKET SIZE, BY GABA AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DYSKINESIA MARKET SIZE, BY GABA AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DYSKINESIA MARKET SIZE, BY GABA AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DYSKINESIA MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DYSKINESIA MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DYSKINESIA MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DYSKINESIA MARKET SIZE, BY VMAT2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DYSKINESIA MARKET SIZE, BY VMAT2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DYSKINESIA MARKET SIZE, BY VMAT2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DYSKINESIA MARKET SIZE, BY ABLATIVE SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DYSKINESIA MARKET SIZE, BY ABLATIVE SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DYSKINESIA MARKET SIZE, BY ABLATIVE SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DYSKINESIA MARKET SIZE, BY DEEP BRAIN STIMULATION (DBS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DYSKINESIA MARKET SIZE, BY DEEP BRAIN STIMULATION (DBS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DYSKINESIA MARKET SIZE, BY DEEP BRAIN STIMULATION (DBS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DYSKINESIA MARKET SIZE, BY INTRAVENOUS (IV) & INFUSION-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DYSKINESIA MARKET SIZE, BY INTRAVENOUS (IV) & INFUSION-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DYSKINESIA MARKET SIZE, BY INTRAVENOUS (IV) & INFUSION-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DYSKINESIA MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DYSKINESIA MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DYSKINESIA MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DYSKINESIA MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DYSKINESIA MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DYSKINESIA MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DYSKINESIA MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DYSKINESIA MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DYSKINESIA MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DYSKINESIA MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DYSKINESIA MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DYSKINESIA MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DYSKINESIA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DYSKINESIA MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DYSKINESIA MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DYSKINESIA MARKET SIZE, BY SPECIALTY CLINICS & REHABILITATION CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DYSKINESIA MARKET SIZE, BY SPECIALTY CLINICS & REHABILITATION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DYSKINESIA MARKET SIZE, BY SPECIALTY CLINICS & REHABILITATION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DYSKINESIA MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DYSKINESIA MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DYSKINESIA MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DYSKINESIA MARKET SIZE, BY INPATIENT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DYSKINESIA MARKET SIZE, BY INPATIENT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DYSKINESIA MARKET SIZE, BY INPATIENT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DYSKINESIA MARKET SIZE, BY OUTPATIENT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DYSKINESIA MARKET SIZE, BY OUTPATIENT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DYSKINESIA MARKET SIZE, BY OUTPATIENT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DYSKINESIA MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DYSKINESIA MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DYSKINESIA MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DYSKINESIA MARKET SIZE, BY SPECIALTY MOVEMENT DISORDER CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DYSKINESIA MARKET SIZE, BY SPECIALTY MOVEMENT DISORDER CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DYSKINESIA MARKET SIZE, BY SPECIALTY MOVEMENT DISORDER CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DYSKINESIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS DYSKINESIA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL DYSKINESIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 202. GCC DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. GCC DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. GCC DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. GCC DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 206. GCC DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 207. GCC DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 208. GCC DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. GCC DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. GCC DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 232. G7 DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. G7 DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. G7 DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. G7 DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 236. G7 DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 237. G7 DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 238. G7 DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. G7 DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 240. G7 DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. G7 DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 242. NATO DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. NATO DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. NATO DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. NATO DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 246. NATO DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 247. NATO DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 248. NATO DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. NATO DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 250. NATO DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. NATO DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES DYSKINESIA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA DYSKINESIA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)